Dimensional Fund Advisors LP Buys 18,602 Shares of Illumina, Inc. $ILMN

Dimensional Fund Advisors LP increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.3% during the first quarter, HoldingsChannel reports. The institutional investor owned 582,797 shares of the life sciences company’s stock after buying an additional 18,602 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Illumina were worth $71,822,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ILMN. Capital World Investors grew its holdings in shares of Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after purchasing an additional 124,323 shares in the last quarter. State Street Corp increased its position in shares of Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after purchasing an additional 190,324 shares during the period. AQR Capital Management LLC raised its stake in Illumina by 30.3% in the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after purchasing an additional 1,028,099 shares in the last quarter. Geode Capital Management LLC raised its stake in Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock valued at $375,260,000 after purchasing an additional 130,139 shares in the last quarter. Finally, Invesco Ltd. lifted its position in Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares during the period. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ILMN shares. Sanford C. Bernstein reiterated a “market perform” rating and set a $215.00 price objective on shares of Illumina in a research note on Friday. Royal Bank Of Canada boosted their target price on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Thursday, May 14th. Canaccord Genuity Group increased their price target on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Nine equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $175.47.

Insider Buying and Selling

In other news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares of the company’s stock, valued at $3,771,540. This represents a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total transaction of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 over the last three months. Insiders own 2.90% of the company’s stock.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported $1.16 billion in revenue, up approximately 9.4%–9.5% year over year, while non-GAAP diluted EPS of $1.31 topped the $1.23 consensus estimate. Clinical demand and NovaSeq X placements were key growth drivers. Illumina Q2 financial results
• Positive Sentiment: Full-year guidance was raised: Management increased fiscal 2026 non-GAAP EPS guidance to $5.30–$5.40 and revenue guidance to approximately $4.60–$4.64 billion, modestly ahead of analyst expectations. Illumina outlook
• Positive Sentiment: Analysts raised price targets: JPMorgan lifted its target to $230 and maintained an “overweight” rating; Stifel raised its target to $225 and assigned a “buy” rating. TD Cowen increased its target to $210 but retained a “hold” rating. These revisions signal greater confidence in Illumina’s earnings outlook, although targets vary considerably.
• Positive Sentiment: AI and drug-discovery opportunities remain a catalyst: CEO Jacob Thaysen highlighted genomic medicine and artificial intelligence applications in life sciences. Eli Lilly also joined Illumina’s Billion Cell Atlas alliance, which aims to create large-scale genomic datasets for identifying disease mechanisms and drug targets. Eli Lilly joins Billion Cell Atlas
• Neutral Sentiment: Investors are taking profits near record levels: With ILMN trading close to its one-year high, the strong results may have prompted a “sell-the-news” response as investors sought evidence of further upside beyond the guidance increase.
• Negative Sentiment: China and margins remain concerns: Greater China revenue declined 12%, while full-year non-GAAP operating-margin guidance remained unchanged at 23.4%–23.6%. Management also expects NovaSeq X instrument-placement growth to moderate year over year in the second half. Illumina China and margin analysis
• Negative Sentiment: Insider selling may add pressure: Reported insider activity over the past six months included 41 sales and one purchase, though such transactions may reflect scheduled or personal portfolio activity rather than a direct view of fundamentals.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $205.10 on Friday. The company has a market cap of $31.03 billion, a price-to-earnings ratio of 38.26, a PEG ratio of 3.03 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The firm has a 50 day simple moving average of $176.70 and a 200 day simple moving average of $147.24. Illumina, Inc. has a one year low of $88.00 and a one year high of $205.93.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 30.54% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the company earned $1.19 earnings per share. The business’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Research analysts predict that Illumina, Inc. will post 5.22 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.